Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

MedImmune and NGM Biopharmaceuticals Announce Agreement

Published: Wednesday, June 19, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Agreement to discover and develop therapies for diabetes and obesity.

AstraZeneca has announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM’s enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity.

EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the known GI hormones, including GLP-1.

EECs are an underexplored source of novel hormones that could play a major role in the positive and negative regulation of metabolism and glucose homeostasis.

NGM has established a proprietary platform capable of isolating and analyzing EECs in order to identify novel secreted peptide hormones that are potentially linked to the profound metabolic effects of bariatric surgery and serve as potential targets for the treatment of metabolic diseases.

MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones.

MedImmune will have the option to license in these EEC targets, and will be responsible for the global development, manufacture and commercialization of compounds resulting from the collaboration.

“We believe that hormones found in the gastrointestinal tract can play an important role in resolving diabetes after bariatric surgery. Through NGM’s innovative research in metabolic disease, we believe our collaboration could lead to potential innovative medicines for diabetes and obesity that will make a difference in patients’ lives,” said Cristina Rondinone, Ph.D., Head of Cardiovascular and Metabolic Disease Innovative Medicines Unit, MedImmune.

Rondinone continued, “Our partnership with NGM complements AstraZeneca’s existing small molecule and biologics portfolio in cardiovascular and metabolic disease, one of our core therapy areas.”

Under the terms of the agreement, MedImmune will make an upfront payment and provide NGM research funding over the course of the collaboration.

If certain development, regulatory and commercial milestones are achieved, NGM will be entitled to receive various payments, as well as royalties on worldwide product sales.

“We are excited to enter into this strategic partnership with MedImmune as it represents a unique opportunity to maximize the full complement of novel hormones secreted by these EECs for drug discovery purposes,” said Jin-Long Chen, Ph.D., founder, president and chief scientific officer of NGM.

Chen continued, “Together, NGM and MedImmune will build upon the culture of scientific excellence at both organizations. With MedImmune’s deep biologics and development expertise, we are confident that we will further enrich the pipeline of therapies for the treatment of diabetes and obesity.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MedImmune, 3M Drug Delivery Partner
The collaboration will focus on developing next generation toll-like receptor (TLR) agonists - promising agents that activate innate immune cells and enhance the visibility of cancer tumors.
Tuesday, September 29, 2015
MedImmune Licenses Inovio Cancer Vaccine
Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine candidates.
Tuesday, August 11, 2015
Medimmune & NIST Partner To Advance Development Of Biological Therapies
Five year partnership will support research to help advance biopharmaceutical development and production.
Monday, February 23, 2015
Astrazeneca Strengthens Partnership with the University of Cambridge
AstraZeneca and MedImmune have entered into four new collaborations.
Saturday, October 18, 2014
MedImmune Acquires Spirogen and Invests in ADC Therapeutics
MedImmune acquires 100% of Spirogen and enters into a collaboration agreement with ADC for two of their oncology programs.
Tuesday, October 15, 2013
MedImmune and WuXi AppTec Announce Joint Venture
The joint venture will develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.
Tuesday, September 11, 2012
MedImmune Announces Winners of European Cancer Research Abstract Competition
MedImmune have announced the winners of its second annual European research abstract competition which highlights the research of the next generation of scientific leaders in cancer research. Students and postdoctoral fellows from across Europe were invited to submit abstracts describing their research in the field of tumour microenvironments as part of the competition sponsored by MedImmune, AstraZeneca's global biologics unit.
Friday, November 05, 2010
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos